UNSPSC 51411801: Acoxatrine

This classification denotes a vasodilating agent with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IGS0KX75Q, chemically known as 2-(4-(acetamidomethyl)-4-phenyl-1-piperidyl)methyl-1,4-benzodioxane but generally known as acoxatrine, which bears US NIH Compound Identifier 68938. European Medicines Agency schedules Acoxatrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05247MIG. The term ACOXATRINE is an International Non-Proprietary Name.

UNSPSC 51411801 Acoxatrine, a Commodity code, covers emergency and hospital medications supplied to state and local emergency services, health agencies, and cooperative purchasing alliances — specifically advanced life support injectable medications like epinephrine, labetalol, adenosine, and diltiazem used by fire rescue services and pharmacy benefit programs. State and local buyers under this code include city fire departments, state health and human services agencies, and multistate cooperative purchasing entities. The work involves supplying FDA-compliant generic and brand-name injectables with firm pricing, warranty against defects, managed expiration tracking (typically nine months or longer shelf life from delivery), rapid fulfillment timelines (often ten calendar days), and compliance with OSHA safety data sheet requirements and Good Manufacturing Practices standards.

Recent opportunities span the Southeast, Texas, and multistate cooperative frameworks. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to Tampa Fire Rescue, a one-year contract estimated at $40,000 with two optional one-year renewals and a 5 percent bid discount for Small Local Business Enterprise participation, due April 8, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI 0017013) in April 2026 to gauge vendor capabilities for direct-to-manufacturer prescription programs, signaling potential future state-level demand. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract terms effective July 1, 2026, across participating state and local government facilities in Minnesota and Oregon. MMCAP evaluations weight price competitiveness at 75 percent, with vendor performance penalties of $200 to $1,500 per violation for reporting or onboarding failures.